You are here: Industry Insights > Vifor Pharma

News List

CSL to acquire Switzerland’s Vifor Pharma for $11.7bn Pharmaceutical-Technology
December 16, 2021
CSL has signed a definitive agreement for the acquisition of all publicly held stakes of Switzerland-based Vifor Pharma in a deal worth $11.7bn (A$16.4bn) in cash.
FDA Approves Korsuva (difelikefalin) Injection for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients drugs
August 26, 2021
Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved Korsuva (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease.
Vifor Pharma gains commercialisation rights for ChemoCentryx’s Avacopan in Asia pharmaceutical-technology
February 16, 2017
Swiss-based Vifor Pharma, a Galenica Group company, has gained commercialisation rights for ChemoCentryx’s Avacopan (CCX168) for orphan and rare renal diseases in Asia, including Japan and the Middle East.